Dr. Aoife Brennan is an experienced physician scientist and drug developer responsible for the successful clinical development and registration of multiple transformative medicines. Aoife has served as Synlogic’s president and chief executive officer since May 2018.
Aoife joined Synlogic in September 2016 as chief medical officer. Prior to Synlogic, Aoife spent six years at Biogen, most recently as vice president and head of the Rare Disease Innovation Unit, developing programs from pre-clinical to commercial. She has led programs across multiple therapeutic areas including the successful late phase development & registration of SPINRAZA® (nusinersen) for spinal muscular atrophy and ALPROLIX® and ELOCTATE® for Hemophilia B and Hemophilia A, respectively.
Aoife serves as a member of the Board of Directors of Cerevance and Fibrogen, Inc, and previously served on the Board of Directors of Ra Pharmaceuticals until its acquisition by UCB. Earlier in her career, Aoife led clinical development at Tolerx, a start-up biotech company focusing on immunotherapy for Type 1 diabetes.